← All trials
NCT04450953
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 12, 2021
- Primary completion
- Feb 29, 2024
- Completion date
- Feb 29, 2024
- First posted
- Jun 30, 2020
- Last posted
- Nov 30, 2021
- Enrollment
- 36
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- CHU BraboisLead sponsor
- University of LorraineSponsor investigator
- University of LorraineStudy chair
- University of LorraineOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.